Physician profile
Marcus L Nichols
NPI 1750350559
$7,573.90
in general payments reported to CMS, 2019-2025
29 companies · $772 in 2025
The $772 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,105 · 2020: $1,119 · 2021: $1,219 · 2022: $1,126 · 2023: $1,049 · 2024: $1,184 · 2025: $772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,984 · Education: $20.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,984.11 |
| Education | $20.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,919.16 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,341.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,033.04 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $836.42 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $367.88 | 2019-2025 | Prolia, Evenity, Otezla |
| Kowa Pharmaceuticals America, INC. | $337.28 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $292.27 | 2019-2022 | |
| Amarin Pharma, INC. | $201.33 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $197.11 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Pfizer INC. | $194.28 | 2019-2024 | |
| Glaxosmithkline, LLC. | $167.19 | 2021-2025 | Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $102.55 | 2022-2024 | Eliquis, Camzyos |
| Abbvie INC. | $88.81 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $87.34 | 2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $77.37 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $69.96 | 2023-2024 | Vyepti |
| Bayer Healthcare Pharmaceuticals INC. | $47.95 | 2021-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $31.71 | 2022 | |
| Novartis Pharmaceuticals Corporation | $28.32 | 2022 | |
| Dexcom, INC. | $23.86 | 2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.88 | 2025 | Caplyta |
| Abbott Laboratories | $15.93 | 2024 | Freestyle Libre 3 |
| Ethicon US, LLC | $15.91 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $14.91 | 2021 | |
| Sumitomo Pharma America, INC. | $14.76 | 2025 | Gemtesa |
| Inspire Medical Systems, INC. | $13.31 | 2024 | Inspire |
| Sanofi-Aventis U.S. LLC | $12.58 | 2020 | |
| Apria Healthcare LLC | $12.09 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $11.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Nichols listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.